Dr. Brandon Biesiadecki's research focuses on improving heart function in diseases where the heart cannot pump enough blood to meet the body's needs. He studies a specific modification of heart muscle proteins that enhances contraction without increasing calcium levels, which could lead to fewer side effects than current treatments. The goal is to develop new therapies that can safely enhance heart performance without the risks associated with traditional medications.

Isabelle Deschenes' lab at Ohio State University focuses on understanding the mechanisms underlying sudden cardiac death, particularly in heart failure patients. They investigate the roles of specific proteins like KChIP2 and JNK2 in heart cell communication and rhythm management. By exploring these pathways, the lab aims to discover new therapeutic strategies to prevent dangerous heart rhythms and improve patient outcomes.

Dr. Krishna Chinthalapudi's lab at Ohio State University focuses on understanding how proteins in the heart, particularly cardiac myosin and its binding partner cMyBP-C, control muscle contraction. This research aims to uncover the molecular mechanisms behind these proteins, which is crucial for developing new treatments for heart diseases like cardiomyopathy. By exploring the structural states of cardiac myosin, the lab hopes to shed light on how these processes affect heart function and could lead to innovative therapies.

Dr. Dmitry Terentyev's lab at Ohio State University focuses on understanding how mitochondrial dysfunction leads to dangerous heart rhythm problems. They study the relationship between mitochondria, calcium signaling, and heart health, particularly under stress. The lab aims to find ways to improve heart function and reduce the risk of fatal arrhythmias, especially in patients with specific genetic conditions or heart diseases.

Dr. Kristin I. Stanford's lab at Ohio State University focuses on understanding how certain lipids, called oxylipins, can help control metabolism and combat obesity and type 2 diabetes. They employ a novel technology called tissue nanotransfection to enhance the production of a specific oxylipin, 1213-diHOME, in the body, aiming to improve energy balance and metabolic health. By exploring these mechanisms, the lab hopes to develop new therapeutic strategies to address growing public health issues related to obesity and diabetes.

Dr. Sandor Gyorke's lab focuses on understanding how a calcium-binding protein called calmodulin regulates heart function. They study how calmodulin is produced from three different genes and how this complexity contributes to precise signaling in heart cells. This research has implications for developing targeted therapies for cardiovascular diseases.